Home » Stocks » SGEN

Seagen, Inc. (SGEN)

Stock Price: $157.50 USD 0.62 (0.40%)
Updated Jun 24, 2021 2:37 PM EDT - Market open
Market Cap 28.80B
Revenue (ttm) 2.27B
Net Income (ttm) 660.65M
Shares Out 181.48M
EPS (ttm) 3.58
PE Ratio 43.95
Forward PE 909.09
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $157.50
Previous Close $156.88
Change ($) 0.62
Change (%) 0.40%
Day's Open 158.25
Day's Range 157.22 - 160.48
Day's Volume 251,183
52-Week Range 133.20 - 213.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOTHELL, Wash.--(BUSINESS WIRE)-- #ASCO2021--Seagen Announces Long-Term Results from Pivotal Trial in Patients with HER2-Positive Breast Cancer During the 2021 ASCO Annual Meeting

3 weeks ago - Business Wire

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday...

3 weeks ago - Business Wire

TOKYO and BOTHELL, Wash., May 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.

1 month ago - PRNewsWire

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)-- #ASCO21--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced updated results fr...

1 month ago - Business Wire

Their revenue prospects are the ticket to future share price performance.

Other stocks mentioned: MRNA, VRTX
1 month ago - The Motley Fool

Although they have been struggling recently, these stocks remain attractive buys over the long term.

Other stocks mentioned: BYND, SNOW
1 month ago - The Motley Fool

Final Trades: Uber, ViacomCBS, Moderna & more

YouTube video

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: MRNA, UBER, VIAC
1 month ago - CNBC Television

Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.

1 month ago - Zacks Investment Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -13.56% and -2.76%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Seagen (NASDAQ:SGEN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 31.63% over the past year to ($0.67), which missed th...

1 month ago - Benzinga

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the first quarter and three months ended March 31, 2021. The Company also highlighted ADCETRIS® (brentuxim...

1 month ago - Business Wire

BOTHELL, Wash.--(BUSINESS WIRE)-- #ASCO2021--Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting

1 month ago - Business Wire

Seattle Genetics (NASDAQ:SGEN) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings announcement.

1 month ago - Benzinga

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.

2 months ago - Zacks Investment Research

TOKYO and BOTHELL, Wash., April 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.

2 months ago - PRNewsWire

The FDA accepts Seagen (SGEN) and Genmab's BLA for tisotumab vedotin under a priority review to treat recurrent/metastatic cervical cancer. A verdict is pending on Oct 10, 2021.

2 months ago - Zacks Investment Research

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority...

Other stocks mentioned: GMAB
2 months ago - Business Wire

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that preclinical data from its pipeline of novel targeted oncology drugs will be presented at the American Association for Can...

2 months ago - Business Wire

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2021 financial results on Thursday, April 29, 2021 after the close of U.S. financial mar...

2 months ago - Business Wire

Horizon Therapeutics has a clear path to significant sales growth.

Other stocks mentioned: ABBV, BMY, HZNP, PFE, VRTX
2 months ago - The Motley Fool

The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

2 months ago - Zacks Investment Research

TOKYO and BOTHELL, Wash., March 26, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:  Kenji Yasukawa, Ph.D.

2 months ago - PRNewsWire

TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing authorizati...

2 months ago - Business Wire

Seagen (SGEN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

3 months ago - Zacks Investment Research

The price is right for these stocks, which are promising big revenue.

Other stocks mentioned: NVAX, VRTX
3 months ago - The Motley Fool

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

If you think ecommerce and digital banking have accelerated in the past year, then you really need to check out promising biotech stocks. The post 7 Biotech Stocks With Catalysts That Go Far Beyond Covi...

Other stocks mentioned: DNLI, FATE, MRNA, MRTX, NVAX, ZLAB
3 months ago - InvestorPlace

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that it has been notified of an unsolicited “mini-tender” offer dated February 22, 2021, made by TRC Capital Investment Corpora...

3 months ago - Business Wire

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at...

4 months ago - Business Wire

Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.

4 months ago - Zacks Investment Research

TOKYO and BOTHELL, Wash., Feb. 18, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced completion of...

4 months ago - PRNewsWire

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of submissions fo...

4 months ago - Business Wire

The European Commission approves Seagen's (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with HER2-positive locally advanced or metastatic breast cancer.

4 months ago - Zacks Investment Research

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced primary results from the pha...

4 months ago - Business Wire

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced results from the second coho...

4 months ago - Business Wire

Seagen (SGEN) surpasses estimates for earnings and revenues in the fourth quarter of 2020. The company provides revenues guidance for 2021.

4 months ago - Zacks Investment Research

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced that the European Commission (EC) has granted marketing authorization for TUKYSA® (tucatinib) in combination with trastuzumab a...

4 months ago - Business Wire

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2020. The Company also highlighted ADCETRIS® (brentuximab v...

4 months ago - Business Wire

Seagen (SGEN) submits a BLA to the FDA for accelerated approval of tisotumab vedotin in patients with recurrent/metastatic cervical cancer, whose disease has progressed on or after chemotherapy.

4 months ago - Zacks Investment Research

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food a...

Other stocks mentioned: GMAB
4 months ago - Business Wire

Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

The rumor mill took hold in late-day trading.

4 months ago - The Motley Fool

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...

Other stocks mentioned: ANNX, ASA, BME, BMEZ, BST, BSTZ, GMAB ...
4 months ago - Seeking Alpha

Revenue growth is just beginning for these companies.

Other stocks mentioned: MRNA, VERX
5 months ago - The Motley Fool

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2020 financial results on Thursday, February 11, 2021 after the close of ...

5 months ago - Business Wire

Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearly 65% year...

5 months ago - GuruFocus

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 2:00 ...

6 months ago - Business Wire

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

Other stocks mentioned: BNTX, CRSP, DNLI, MRTX, NVAX, ZLAB
6 months ago - InvestorPlace

About SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. I... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
SGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for Seagen stock is "Buy." The 12-month stock price forecast is 189.13, which is an increase of 20.08% from the latest price.

Price Target
$189.13
(20.08% upside)
Analyst Consensus: Buy